Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer

T cells are important for controlling ovarian cancer (OC). We previously demonstrated that combinatorial use of a personalized whole-tumor lysate-pulsed dendritic cell vaccine (OCDC), bevacizumab (Bev), and cyclophosphamide (Cy) elicited neoantigen-specific T cells and prolonged OC survival. Here, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanyi, Janos L., Chiang, Cheryl L.-L., Chiffelle, Johanna, Thierry, Anne-Christine, Baumgartener, Petra, Huber, Florian, Goepfert, Christine, Tarussio, David, Tissot, Stephanie, Torigian, Drew A., Nisenbaum, Harvey L., Stevenson, Brian J., Guiren, Hajer Fritah, Ahmed, Ritaparna, Huguenin-Bergenat, Anne-Laure, Zsiros, Emese, Bassani-Sternberg, Michal, Mick, Rosemarie, Powell, Daniel J., Coukos, George, Harari, Alexandre, Kandalaft, Lana E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960755/
https://www.ncbi.nlm.nih.gov/pubmed/33723260
http://dx.doi.org/10.1038/s41541-021-00297-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960755/
https://www.ncbi.nlm.nih.gov/pubmed/33723260
http://dx.doi.org/10.1038/s41541-021-00297-5

Ejemplares similares